ESMO 2023 | The future of amivantamab and lazertinib in EGFR-mutant NSCLC

Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea, comments on the next steps for the Phase III MARIPOSA (NCT04487080) trial of amivantamab, an EGFR-MET bispecific antibody, with lazertinib, a tyrosine kinase inhibitor (TKI), versus osimertinib in EGFR-mutated non-small cell lung cancer (NSCLC) in the first-line setting. A circulating tumor (ctDNA) analysis is underway, which may have potential to be a predicative biomarker for patients who will positively respond to the combination therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.